Brevagenplus

Phenogen Sciences sought to educate physicians and patients about the need for the BREVAGenplus scientifically validated test that assesses the risk of sporadic (non-hereditary) breast cancer in African American, Caucasian, and Hispanic patients. The test results are based upon clinical risk factors such as age and age at child birth, as well as genetic markers - Single Nucleotide Polymorphisms (SNPs). Test results enable risk reduction plans to be enacted.  MDCG was contacted by Phenogen Sciences seeking new messaging and a new visual identity for BREVAGenplus.  This strategy was created and carried forward as the test grew into new populations with an expanded name, developing a new logo and collateral in both English and Spanish. http://brevagenplus.com/